CAS: 1218777-13-9; (E)-5-((5-(4-Fluorophenyl)Furan-2-yl)Methylene)Thiazolidine-2,4-Dione
该化合物是某些酶的选择性抑制剂,尤其是那些参与细胞信号路径监管的酶,经常在药理研究的背景下加以研究,特别是研究其在各种疾病(包括癌症和炎症)中的潜在治疗用途,该化合物通常具有与目标的具体结合性,允许生物过程的调节.CAY1005的特点是其分子结构,其中包括有助于其生物活动的功能组.在实验室环境中,该化合物通常用于分析酶活动和细胞反应.与许多化学物质一样,应参考安全数据表和处理准则,以确保适当使用和了解与该化合物有关的任何潜在危害.
- 英文名称(E)-5-((5-(4-Fluorophenyl)Furan-2-yl)Methylene)Thiazolidine-2,4-Dione
- 中文名称(5E)-5-[[5-(4-氟苯基)-2-呋喃基]亚甲基]-2,4-噻唑烷二酮
- IUPAC名称(E)-5-((5-(4-fluorophenyl)furan-2-yl)methylene)thiazolidine-2,4-dione
- 其它别名5-((5-(4-Fluorophenyl)Furan-2-yl)Methylene)Thiazolidine-2,4-Dione; 2,4-Thiazolidinedione, 5-[[5-(4-Fluorophenyl)-2-Furanyl]Methylene]-; (E)-5-((5-(4-Fluorophenyl)Furan-2-yl)Methyle
- CAS编号1218777-13-9
- MFCD编号:MFCD00640727
- FDA UNII编号:S8TQU87RAT
- 分子式:C14H8FNO3S分子量:289.29
- 产品CID: 305710
- 产品分类生物化工 → 抑制剂 → PI3K/Akt/mTOR抑制剂(PI3K/Akt/mTOR)
物理性质
合成工艺路线路线简述
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2912110000-甲醛
2912120000-乙醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Tyagi S, Sharma S, Budhiraja RD. Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats. Can J Physiol Pharmacol. 2012 Jul;90(7):881-5. doi: 10.1139/y2012-089. Epub 2012 Jun 25.
合成参考文献
参考文献:10.1016/j.bmc.2023.117561
摘要:Takarada JE, Cunha MR, Almeida VM, Vasconcelos SNS, Santiago AS, Godoi PH, Salmazo A, Ramos PZ, Fala AM, de Souza LR, Da Silva IEP, Bengtson MH, Massirer KB, Couñago RM. Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors. Bioorg Med Chem. 2024 Jan 15;98():117561. doi: 10.1016/j.bmc.2023.117561.
📝 需求与反馈
尽可能描述清楚需求与问题信息
